FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1143-1154 September 11, 2008 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

More than half a million patients receive the diagnosis of squamous-cell carcinoma of the head and neck worldwide each year. In this disease, which primarily affects the oropharynx, oral cavity, hypopharynx, and larynx, smoking and alcohol abuse are major risk factors. Symptoms vary, depending on the site of origin, and can include a sore throat, dysphagia, odynophagia, and hoarseness. On examination, patients often have an identifiable primary site and a palpable neck mass. A multidisciplinary approach is important in treating these patients, given the complexity of the treatment and the acute and long-term complications that result from chemotherapy, radiation therapy, . . . [Full Text of this Article]

Molecular Progression

Signal Transduction of EGFR

HPV and Antitumor Vaccine

Treatment

Strategies for Therapy

Concurrent Chemoradiotherapy

Definitive Chemoradiotherapy

Postoperative Chemoradiotherapy

Sequential Chemoradiotherapy

Docetaxel, Cisplatin, and Fluorouracil

            Induction Therapy

            Toxic Effects

Pros and Cons of Induction Therapy

Cetuximab

            Role of Biologic Agents

            With Radiation Therapy

            After Recurrence

Future Directions

Source Information

From the Department of Medical Oncology, Dana–Farber Cancer Institute; the Department of Medicine, Brigham and Women's Hospital; and the Department of Medicine, Harvard Medical School — all in Boston (R.I.H.); and the Department of Hematology–Oncology, Winship Cancer Institute, Emory University, Atlanta (D.M.S.).

Address reprint requests to Dr. Haddad at the Dana–Farber Cancer Institute, 44 Binney St., Boston, MA 02115, or at robert_haddad@dfci.harvard.edu.

This article has been cited by other articles:

• Dowejko, A., Bauer, R. J., Muller-Richter, U. D.A., Reichert, T. E. (2009). The human homolog of the Drosophila headcase protein slows down cell division of head and neck cancer cells. Carcinogenesis 30: 1678-1685 [Abstract] [Full Text]  
• Haddad, R. I., Tishler, R. B., Norris, C., Goguen, L., Balboni, T. A., Costello, R., Wirth, L., Lorch, J., Andreozzi, B., Annino, D., Posner, M. R. (2009). Phase I Study of C-TPF in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. JCO 27: 4448-4453 [Abstract] [Full Text]  
• Hamberg, P., Verweij, J. (2009). Phase I Drug Combination Trial Design: Walking the Tightrope. JCO 27: 4441-4443 [Full Text]  
• Haddad, R. I., Posner, M. R. (2009). Induction Chemotherapy in Head and Neck Cancer. JCO 27: e52-e53 [Full Text]  
• Beitler, J. J., Cooper, J. S. (2009). Reply to R.I. Haddad et al. JCO 27: e54-e54 [Full Text]  
• Amin, A.R.M. R., Kucuk, O., Khuri, F. R., Shin, D. M. (2009). Perspectives for Cancer Prevention With Natural Compounds. JCO 27: 2712-2725 [Abstract] [Full Text]  
• Amin, A.R.M. R., Khuri, F. R., Chen, Z., Shin, D. M. (2009). Synergistic Growth Inhibition of Squamous Cell Carcinoma of the Head and Neck by Erlotinib and Epigallocatechin-3-Gallate: The Role of p53-Dependent Inhibition of Nuclear Factor-{kappa}B. Cancer Prevention Research 2: 538-545 [Abstract] [Full Text]